HC Wainwright Has Lowered Expectations for BioNTech (NASDAQ:BNTX) Stock Price

BioNTech (NASDAQ:BNTX - Get Free Report) had its price objective lowered by equities research analysts at HC Wainwright from $145.00 to $138.00 in a report released on Monday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's target price would indicate a potential upside of 31.47% from the stock's previous close. HC Wainwright also issued estimates for BioNTech's Q4 2026 earnings at $0.88 EPS.

A number of other equities research analysts have also commented on BNTX. The Goldman Sachs Group began coverage on BioNTech in a research report on Thursday, May 29th. They issued a "neutral" rating and a $110.00 price target on the stock. Morgan Stanley reduced their target price on BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a report on Tuesday, May 6th. JPMorgan Chase & Co. lowered their price target on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a report on Thursday, May 22nd. Canaccord Genuity Group restated a "buy" rating and issued a $171.44 price target on shares of BioNTech in a research report on Tuesday, March 11th. Finally, Leerink Partners set a $112.00 price objective on shares of BioNTech in a research report on Monday, June 2nd. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $137.86.

BioNTech Trading Down 1.3%

Shares of BioNTech stock traded down $1.36 during trading on Monday, hitting $104.97. The company's stock had a trading volume of 765,167 shares, compared to its average volume of 950,009. The stock has a market cap of $25.23 billion, a price-to-earnings ratio of -30.87 and a beta of 1.29. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49. The stock has a 50-day moving average price of $101.37 and a two-hundred day moving average price of $107.89. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.18 and a quick ratio of 10.02.

Institutional Investors Weigh In On BioNTech

Several large investors have recently modified their holdings of BNTX. FMR LLC grew its holdings in BioNTech by 22.2% during the fourth quarter. FMR LLC now owns 7,701,476 shares of the company's stock valued at $877,583,000 after purchasing an additional 1,401,547 shares during the period. Flossbach Von Storch SE lifted its position in shares of BioNTech by 1.1% during the 4th quarter. Flossbach Von Storch SE now owns 4,406,843 shares of the company's stock valued at $502,160,000 after buying an additional 47,236 shares during the last quarter. Capital International Investors increased its holdings in BioNTech by 38.6% in the 4th quarter. Capital International Investors now owns 1,415,566 shares of the company's stock worth $161,304,000 after acquiring an additional 394,434 shares during the last quarter. BNP Paribas Financial Markets raised its stake in BioNTech by 94.6% in the 1st quarter. BNP Paribas Financial Markets now owns 1,195,470 shares of the company's stock valued at $108,859,000 after acquiring an additional 581,173 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in BioNTech by 18,892.9% during the first quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company's stock worth $63,593,000 after purchasing an additional 694,691 shares during the period. Hedge funds and other institutional investors own 15.52% of the company's stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.